On November 20, 2018 AVEO Oncology (NASDAQ:AVEO) reported that Michael Bailey, president and chief executive officer, will present at the 30th Annual Piper Jaffray Healthcare Conference in New York on Wednesday, November 28, 2018 at 2:30 p.m. Eastern Time (Press release, AVEO, NOV 20, 2018, View Source [SID1234531508]). The conference is being held at the Lotte New York Palace Hotel.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the webcast will be archived for 30 days following the presentation date.

On November 20, 2018 Cernostics, developer of next-generation cancer diagnostics and prognostics, reported that it has received a U.S. Patent and a European Notice to Grant for the company’s TissueCypher Barrett’s Esophagus Assay, adding protection to previously awarded foundational, platform patents granted in 2014 (Press release, Cernostics, NOV 20, 2018, View Source [SID1234531530]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Earlier this month, Cernostics received notification from the European Patent Office that claims will be issued for its patent entitled "Systems and Compositions for Diagnosing Barrett’s Esophagus and Methods for Using the Same." This notice comes on the heels of a recent issuance of a corresponding U.S. patent (U.S. Patent No. 10,018,631).

Cernostics’ recent patent claims relate to the company’s clinical test for predicting disease progression in patients with BE and assessment of the likelihood that BE may further develop into esophageal adenocarcinoma (EAC). The patents support a multiplexed evaluation of how protein biomarkers are expressed in various gastrointestinal tissue specimens obtained from BE patients.

Cernostics’ CEO, Mike Hoerres, says, "Our TissueCypher Barrett’s Esophagus Assay was developed as a Laboratory Developed Test for the US market and can be developed as an In Vitro Diagnostic for ex-U.S. markets to assess progression of Barrett’s to esophageal cancer. This technology may help clinicians determine personalized care pathways – establishing which BE patients will likely benefit from endoscopic eradication therapies and what are optimal surveillance intervals for future endoscopies."

About Barrett’s

BE affects more than three million Americans, occurring when chronic exposure to stomach acid causes the esophageal cell lining to deteriorate and undergo changes that can create an environment for cancer. Without treatment, Barrett’s can lead to EAC, with a poor 5-year survival of less than 20%[1]. Today, Barrett’s is commonly managed by surveillance, involving regular endoscopic procedures with biopsy, monitoring disease progression, and GERD-related drug therapy to control symptoms and prevent esophageal injury.

On November 20, 2018 Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, reported that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, and Gregory K. Chow, Senior Vice President and Chief Financial Officer, will participate at upcoming investor conferences, will hold a key opinion leader (KOL) event for the investment community, and will present data at the upcoming 60th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition (Press release, Aptose Biosciences, NOV 20, 2018, View Source [SID1234531491]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Piper Jaffray 19th Annual Health Care Conference
Time: 4:00 pm ET
Date: Tuesday, November 27, 2018
Live Webcast: Piper Jaffray Conference Aptose Webcast Link
BMO Capital Markets Prescriptions for Success Healthcare Conference
Time: 11:40 am ET
Date: Wednesday, December 12, 2018
Live Webcast: BMO Capital Markets Aptose Webcast Link
Key Opinion Leader Breakfast: Novel Treatment for AML and B-cell Cancers
Time: 9:00 – 10:30 am ET
Date: Wednesday, December 12, 2018
Location: Lotte New York Palace Hotel, New York, NY
Live Webcast: Aptose KOL Presentation Webcast Link
The KOL event hosted by Aptose will feature Brian Druker, M.D, Director of Oregon Health & Science University’s Knight Cancer Institute. Dr. Druker is well known for his pioneering role in developing Gleevec for patients with chronic myeloid leukemia (CML) and for his efforts to accelerate the development of novel therapies for the treatment of acute myeloid leukemia (AML). At the KOL event, Dr. Druker will discuss the evolution of kinase inhibitors as anticancer drugs, review the current treatment landscape in AML and B-cell cancers, examine the unmet medical needs for these patient populations, and highlight his experience with Aptose’s CG-806 to potentially address these treatment challenges. Following Dr. Druker, the Aptose Biosciences management team will provide an update on CG-806, which is expected to enter clinical studies in early 2019.

The breakfast event is by invitation only (contact Morgen Alden, [email protected]) and will also be accessible by webcast.

American Society of Hematology (ASH) (Free ASH Whitepaper) Meeting
Time: 6:00 – 8:00 pm PT
Date: December 2, 2018
Location: San Diego Convention Center, San Diego, CA
Aptose previously announced that preclinical data for its pan-FLT3/pan-BTK inhibitor CG-806 will be presented in two separate posters at the 60th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition on Sunday, December 2, 2018 from 6:00-8:00 pm PT in San Diego, CA (link to announcement).

On November 20, 2018 Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, reported that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the 30th Annual Piper Jaffray Healthcare Conference (Press release, Syros Pharmaceuticals, NOV 20, 2018, View Source [SID1234531509]). Details are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

30th Annual Piper Jaffray Healthcare Conference
Date: Tuesday, November 27
Presentation Time: 4:30 p.m. ET
Location: Lotte New York Palace, 455 Madison Avenue, New York, NY

A live webcast of the presentation will be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay will be available for approximately 30 days following the fireside chat

On November 20, 2018 Clovis Oncology, Inc. (NASDAQ:CLVS) reported that the United States Patent and Trademark Office issued United States Patent 10,130,636 with claims directed to methods of treating cancer with high dosage strength rucaparib camsylate formulations (Press release, Clovis Oncology, NOV 20, 2018, View Source [SID1234531510]). The patent claims cover methods of treating cancer with commercial Rubraca product, including all commercial dosage strengths (200, 250 and 300mg). The high dosage strength rucaparib formulation patent expires in 2035, and will join multiple patents directed to rucaparib, rucaparib camsylate, and methods of treatment as the 11th Orange Book-listed patent for rucaparib.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We have multiple families of patents protecting Rubraca in the U.S., including composition of matter, salts/polymorphs, dosage forms and formulations, and methods of use, and we continue to add new patents, including this high dosage strength method of treatment patent," said Patrick J. Mahaffy, President and CEO of Clovis Oncology. "Each additional patent provides further protection for Rubraca, and this is relevant not only to our current indications in ovarian cancer, but also to multiple potential additional indications based on our ongoing and substantial clinical development programs."

About Rubraca (rucaparib)

Rubraca is an oral, small molecule inhibitor of PARP1, PARP2 and PARP3 being developed in multiple tumor types, including ovarian, metastatic castration-resistant prostate, and bladder cancers, as monotherapy, and in combination with other anti-cancer agents. Exploratory studies in other tumor types are also underway. Clovis holds worldwide rights for Rubraca. Rubraca is an unlicensed medical product outside of the U.S. and Europe.